Sign In
Buy NDAQ
$77.65
-3.96 (-4.85%)
At Close: Jun 25, 2026
Nasdaq Reports September 2024 Volumes and 3Q24 Statistics
04:45pm, Monday, 07'th Oct 2024
NEW YORK, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today reported monthly volumes for September 2024, as well as quarterly volumes, estimated revenue capture, number of listings, and in
Luna Innovations Announces Receipt of Nasdaq Staff Determination Letter
04:30pm, Monday, 07'th Oct 2024
ROANOKE, Va,--(BUSINESS WIRE)--Luna Innovations Incorporated (Nasdaq: LUNA) (the “Company”), a global leader in advanced fiber optic-based technology, today announced that on October 1, 2024, it r
Nasdaq: Tailwinds In IPO Activity And Software Company Acquisitions
04:22pm, Monday, 07'th Oct 2024
Nasdaq's diversified business model, with strong segments in Capital Access Platforms, Financial Technology, and Market Services, ensures stable revenue and hedges against downturns. The IPO market is
ATLANTA and VANCOUVER, British Columbia, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (NASDAQ: VIRI) (the “Company”), and Wex Pharmaceuticals, Inc. (“WEX”), a wholly owned subsi
Meihua International Medical Technologies Co., Ltd Regains Compliance with Nasdaq Minimum Bid Price Requirement
06:00am, Monday, 07'th Oct 2024
YANGZHOU, China , Oct. 7, 2024 /PRNewswire/ -- Meihua International Medical Technologies Co., Ltd. ("MHUA" or the "Company") (Nasdaq: MHUA), a reputable manufacturer and provider of Class I, II, and I
Strong Performance by Nasdaq Golden Dragon China Index and Related ETFs
12:10am, Sunday, 06'th Oct 2024
During China's "Golden Week" holiday, overseas Chinese stocks and funds experienced notable gains. The Nasdaq Golden Dragon China Index increased by 3.1%, reaching its highest level since February 2,
You'll Never Guess the Best-Performing Stock in the Nasdaq-100 Last Quarter. Is It Still a Buy?
07:39am, Saturday, 05'th Oct 2024
Hint: It wasn't Nvidia.
Is It Time to Buy September's Worst-Performing Nasdaq Stocks?
04:00am, Saturday, 05'th Oct 2024
September is typically a bad month for stocks, but the Nasdaq still gained.
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 04'th Oct 2024
NAARDEN, the Netherlands and MIAMI, Oct. 04, 2024 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutic
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:15pm, Friday, 04'th Oct 2024
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of
bluebird bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 04'th Oct 2024
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Compensation Committee of the Company's Board of Directors approved the grant of inducement awards of 242
Urgently Notified By Nasdaq Of Non-Compliance With Nasdaq Minimum Bid Price Requirement
04:05pm, Friday, 04'th Oct 2024
Intends to Cure the Deficiency and Return to Compliance with Nasdaq Standard Intends to Cure the Deficiency and Return to Compliance with Nasdaq Standard
Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 04'th Oct 2024
WALTHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company approved the grant of equity awards to one new employee with a grant da
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 04'th Oct 2024
BRISBANE, Calif., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on October 2, 2024, the Compensation Committee granted inducement awards consisting of a
Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 04'th Oct 2024
THOUSAND OAKS, Calif.--(BUSINESS WIRE)---- $ATRA #CART--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell pl
